Failed Back Surgery Syndrome – Persistent Spinal Pain
Persistent Spinal Pain Syndrome Type 2 (PSPS-T2), formerly termed Failed Back Surgery Syndrome (FBSS), describes chronic low-back and/or radicular pain that persists or recurs after one or more spinal operations. The underlying pathophysiology is multifactorial and may involve postoperative nerve root injury, epidural fibrosis, and recurrent foraminal or central stenosis. Other factors include facet degeneration, discogenic pathology, or segmental instability. Central sensitization mechanisms can perpetuate Persistent Spinal Pain (Nissen et al., 2018; Palmer et al., 2019).
Understanding Persistent Spinal Pain and Its Treatment Options
Spinal Cord Stimulation (SCS) has become one of the most advanced and effective treatment options for patients who continue to experience significant back or leg pain after one or more spine surgeries—a condition now termed Persistent Spinal Pain Syndrome Type 2 (PSPS-T2). Many individuals with this condition have already tried medications, physical therapy, and injections, or even additional surgeries, yet their pain persists.
Persistent Spinal Pain is a debilitating condition that affects many individuals, often leading to significant lifestyle changes.
In PSPS-T2, a major component of the pain is often neuropathic, described as burning, electric, sharp, or shooting. This type of pain typically responds poorly to standard medications (Palmer et al., 2019). SCS delivers controlled electrical pulses to the spinal cord to reduce these abnormal pain signals before they reach the brain.
The scientific evidence supporting SCS is strong. One of the key randomized controlled studies showed that patients receiving SCS experienced significantly greater pain reduction, improved physical function, and higher satisfaction. They also had reduced reliance on medications compared with those treated with medical therapy alone (Kumar et al., 2007).
Modern technological advancements have further expanded the benefits of SCS. High-frequency stimulation at 10 kHz, for example, provides consistent relief for both back and leg pain without producing tingling sensations, which some patients find uncomfortable (Kapural et al., 2015). This newer approach has allowed SCS to help a broader range of PSPS-T2 patients, including those with severe axial low-back pain.
Long-term studies also show durable outcomes. In real-world follow-up, most patients who benefit from SCS during the initial trial continue to experience meaningful relief for many years after implantation (Nissen et al., 2018).
Finally, comprehensive comparative research including a 2025 network meta-analysis evaluating all major treatments for PSPS-T2 found neuromodulation therapies like SCS to provide the most effective overall pain reduction and improvements in daily functioning (Goudman et al., 2025).
Managing Persistent Spinal Pain effectively requires a comprehensive understanding of the various treatment modalities available.
For patients whose pain persists despite conventional treatments, SCS offers a scientifically validated, reversible, and highly targeted solution designed to restore comfort, mobility, and quality of life.
SCS Procedure & Targets in Failed Back Surgery Syndrome / Persistent Spinal Pain
Persistent Spinal Pain can often lead to a decreased quality of life, making effective treatments essential.
Spinal Cord Stimulation (SCS) is a minimally invasive neuromodulation therapy designed to directly address chronic back and leg pain in patients with Failed Back Surgery Syndrome / Persistent Spinal Pain Syndrome Type 2 (PSPS-T2).
Patients dealing with Persistent Spinal Pain may find relief through various treatment options tailored to their specific needs.
Step 1: The Trial Procedure
The process begins with a temporary trial—an essential step that allows patients to experience the therapy before committing to a permanent implant.
The physician places thin, flexible leads through a needle into the epidural space, without the need for open surgery.
These leads connect to an external pulse generator worn on a belt or clothing.
Over the next 3–7 days, patients test whether stimulation meaningfully reduces their pain or improves daily functioning.
A successful trial typically means at least 50% pain reduction, improved sleep, better mobility, or a decrease in medication use. Long-term studies show that patients who respond well during the trial are highly likely to maintain meaningful benefit after permanent implantation (Nissen et al., 2018).
Step 2: Permanent Implantation
If the trial is successful, a permanent system is implanted.
The leads are placed in the same epidural location but secured more firmly.
A small implantable pulse generator (IPG) is positioned under the skin, usually in the upper buttock or lower abdomen.
Understanding the nuances of Persistent Spinal Pain is crucial for patients considering their treatment options.
Modern rechargeable IPGs last many years and support advanced waveforms such as 10 kHz high-frequency stimulation, which does not produce paresthesia (Kapural et al., 2015).
The entire procedure typically takes under an hour, and most patients return home the same day.
Target Locations: Tailored to the Pain Pattern
Precise targeting is key to the success of SCS. The placement of leads is customized based on the dominant pain type:
Radicular leg or sciatic pain:
Leads are placed around the mid-thoracic spine (T8–T10), corresponding to lumbar and sacral dermatomes. This placement is well established in major clinical studies (Kumar et al., 2007).
Central or axial low-back pain:
Traditional low-frequency stimulation is often less effective for midline back pain. Modern high-frequency (10 kHz) and burst stimulation have shown superior coverage of deep dorsal horn circuits, providing robust relief without paresthesia (Kapural et al., 2015; Palmer et al., 2019).
Persistent Spinal Pain can be challenging to manage, but innovative therapies continue to emerge.
Why These Targets Work
In PSPS-T2, ongoing pain may come from nerve root irritation, postoperative scarring, altered spinal biomechanics, and central sensitization. SCS aims to normalize these dysregulated pathways. By placing leads directly over the segments transmitting pain signals, stimulation effectively “rebalances” how the spinal cord processes pain.
Clinical Outcomes & Long-Term Efficacy of SCS in Failed Back Surgery Syndrome / Persistent Spinal Pain
Spinal Cord Stimulation (SCS) is one of the most extensively studied advanced treatments for patients with Failed Back Surgery Syndrome / Persistent Spinal Pain Syndrome Type 2 (PSPS-T2). These patients frequently continue to experience severe neuropathic leg pain, axial back pain, or combined pain patterns despite surgery, medications, physical therapy, and injections. Across multiple randomized trials, cohort studies, and systematic reviews, SCS consistently demonstrates meaningful and sustained improvement.
Persistent Spinal Pain remains a topic of active research as clinicians seek more effective treatment strategies.
Short-Term Clinical Outcomes
Short-term outcomes for SCS in PSPS-T2 are highly favorable. The landmark randomized controlled trial comparing SCS with conventional medical management showed superior reductions in radicular leg pain, improved physical function, and lower medication use in the SCS group (Kumar et al., 2007). Additional randomized evidence confirms that SCS improves quality of life, daily functioning, and patient satisfaction within weeks of implantation (North et al., 2011; Palmer et al., 2019).
For those suffering from Persistent Spinal Pain, early intervention can significantly impact long-term outcomes.
Modern waveforms have amplified these benefits. High-frequency 10 kHz stimulation demonstrated significantly higher responder rates and superior reduction in both back and leg pain compared with traditional low-frequency stimulation (Kapural et al., 2015).
Long-Term Efficacy and Durability
One of the strongest advantages of SCS is long-term stability of results. Longitudinal data show that most patients who respond during the trial phase maintain substantial pain relief for years. In a large 20-year cohort, 74% of patients continued to use SCS at final follow-up, and 69% reported meaningful global improvement (Nissen et al., 2018). Device longevity, programmability, and the ability to adapt stimulation to evolving pain patterns all contribute to sustained efficacy.
Long-term outcomes include:
- Persistent reduction in neuropathic leg pain (Nissen et al., 2018),
- Clinically significant improvement in back pain (Kapural et al., 2015),
- Decreased opioid consumption (Kumar et al., 2007),
- Enhanced quality of life and daily functioning (North et al., 2011; Palmer et al., 2019),
- Durable satisfaction rates over multi-year follow-up (Nissen et al., 2018).
Comparative Effectiveness
High-level comparative evidence strongly favors SCS. A 2025 network meta-analysis evaluating all major PSPS-T2 treatments identified neuromodulation as the most effective intervention for overall pain reduction and functional improvement, outperforming conservative measures, pharmacologic therapies, and minimally invasive injections (Goudman et al., 2025). Systematic reviews have similarly concluded that SCS is the only therapy with strong evidence for sustained pain relief in FBSS/PSPS-T2 populations (Palmer et al., 2019).
Side Effects & Safety Profile
Spinal Cord Stimulation (SCS) has a well-established safety profile, supported by decades of randomized trials, long-term observational studies, and systematic reviews. Most side effects are mild and temporary, reflecting the minimally invasive and reversible nature of the procedure.
Device-related complications are well-documented across multiple cohorts. Large observational series report lead migration, hardware malfunction, and superficial infection as the most frequent issues (Nissen et al., 2018; Pain Physician, 2016). Migration rates have decreased significantly with modern lead designs, and most cases are corrected through reprogramming rather than revision surgery. Infection occurs in a small minority of patients and is usually managed with antibiotics; full system removal is required only in select cases (Palmer et al., 2019).
Importantly, severe neurological injury is extremely rare. Even in high-volume centers, the incidence of epidural hematoma or neurologic deficit remains far below that observed with repeat spine surgery or intrathecal catheter systems (Pain Physician, 2016; North et al., 2005). Long-term safety is also well supported: multi-year follow-up studies show stable device performance and high continuation rates, with most patients using SCS safely for many years (Nissen et al., 2018).
Compared with chronic opioid therapy—which carries risks of dependency, hormonal suppression, and systemic toxicity—SCS avoids whole-body side effects and offers a favorable long-term risk–benefit balance.
Patients with Persistent Spinal Pain should be aware of the potential side effects associated with various treatments.
SCS vs Other Treatment Options
Patients with Failed Back Surgery Syndrome / Persistent Spinal Pain Syndrome Type 2 (PSPS-T2) often try multiple treatments—medications, injections, physical therapy, or even repeat surgeries—before considering neuromodulation. However, extensive clinical evidence shows that Spinal Cord Stimulation (SCS) offers superior and more durable relief compared with nearly all conventional approaches, particularly when neuropathic leg or mixed back-and-leg pain is present.
Conservative treatments, including NSAIDs, neuropathic agents, antidepressants, and opioids, provide limited long-term benefit for many PSPS-T2 patients. Medication-based management is often restricted by side effects such as sedation, cognitive impairment, hormonal dysfunction, or dependency risks (Palmer et al., 2019). In contrast, SCS targets the pain pathways directly within the spinal cord, reducing the need for systemic drugs and avoiding whole-body side effects (Kumar et al., 2005).
Epidural steroid injections, adhesiolysis, and facet interventions may offer temporary relief but rarely sustain benefits beyond several months. Systematic reviews, including those from Pain Physician (2016), emphasize that interventional procedures often require repetition and do not modify the underlying neuropathic processes driving PSPS-T2. SCS, on the other hand, shows sustained improvements in both pain and functional capacity, especially for radicular symptoms (North et al., 2005; Kumar et al., 2007).
Repeat spine surgery generally yields diminishing returns. Studies comparing re-operation to SCS demonstrate significantly lower success rates for additional surgeries and a higher risk of complications. A major multicenter randomized trial showed that SCS provided better pain relief, improved quality of life, and reduced disability compared with repeat decompression or fusion procedures (North et al., 2011). This makes SCS a preferred option when structural compression is no longer the primary driver of pain.
Intrathecal drug delivery systems may be considered for severe refractory cases, but they carry risks such as catheter complications, granuloma formation, and opioid-related toxicity. Comparative analyses indicate that SCS offers a more favorable safety and long-term tolerability profile (Pain Physician, 2016).
Persistent Spinal Pain presents unique challenges, and understanding these can aid in better treatment planning.
Finally, high-level comparative evidence—including a 2025 network meta-analysis—found neuromodulation therapies, particularly SCS, to be the most effective overall treatment for PSPS-T2, outperforming conservative care, injections, and minimally invasive procedures (Goudman et al., 2025).
Overall, SCS stands out as the most evidence-supported, durable, and patient-centered option for managing persistent spinal pain after surgery.
What to Expect During Recovery and Follow-Up
Recovery after Spinal Cord Stimulation (SCS) is generally smooth, and most patients are able to return home the same day. Because the procedure is minimally invasive, the initial healing period is considerably shorter than that of traditional spine surgery. Understanding what happens during recovery and follow-up can help patients feel confident and prepared throughout the process.
Immediately After the Procedure
Mild soreness around the lead insertion site or the implantable pulse generator (IPG) pocket is normal and typically improves over several days. Patients are encouraged to walk and resume light activities, while avoiding bending, twisting, or lifting heavy objects for the first few weeks. This allows the leads to stabilize and reduces the risk of migration—one of the most common early technical complications reported in long-term studies (Nissen et al., 2018).
Coping strategies for those with Persistent Spinal Pain can greatly enhance quality of life.
Early Follow-Up and Programming
Within the first 1–2 weeks, patients return for an initial programming session. This is when the stimulation settings are customized to their pain pattern. Because SCS is highly adjustable, most patients require several fine-tuning sessions in the first months to achieve optimal relief. Modern devices allow adjustments in frequency, amplitude, and waveform, enabling precise targeting of pain pathways (Kapural et al., 2015).
Timeline of Improvement
Many patients experience meaningful pain relief within days of activation, especially for neuropathic leg pain. Back pain relief may take longer as stimulation patterns are refined. Clinical trials consistently show that functional improvements—including better mobility, sleep, and daily activity—emerge steadily over the first 4–12 weeks (Kumar et al., 2007; Palmer et al., 2019).
Long-Term Follow-Up
Ongoing follow-up visits ensure the system continues working at its best. Devices can be reprogrammed at any time if pain patterns change, making SCS adaptable across the patient’s lifespan. Long-term observational research shows that most individuals continue using and benefiting from their device for many years, supported by stable performance and low complication rates (Nissen et al., 2018).
Overall, patients can expect a manageable recovery, personalized optimization of their therapy, and long-term support to maintain the best possible pain control.
Persistent Spinal Pain can affect emotional health, and addressing these aspects is equally important in treatment.
Persistent Spinal Pain can affect emotional health, and addressing these aspects is equally important in treatment.
The effectiveness of spinal cord stimulation depends strongly on patient selection and clinical characteristics. Neuropathic radicular pain, clearly defined dermatomal symptoms, and unsuccessful response to conservative therapy are among the strongest predictors of benefit (Palmer et al., 2019). Patients with predominantly mechanical pain or untreated structural pathology typically require additional evaluation or corrective treatment before considering SCS.
The trial stimulation phase remains the most reliable predictor of long-term success. Patients who achieve at least 50 percent pain relief during the temporary trial have a significantly higher likelihood of maintaining durable improvement after permanent implantation (North et al., 2005).
Psychological factors also influence outcomes. Patients with stable mood, manageable anxiety, and realistic expectations respond more consistently, whereas depression, high catastrophizing, and unaddressed psychological distress are associated with reduced effectiveness (Palmer et al., 2019).
Technical considerations play a role as well. Optimal lead placement, early identification of hardware issues, and timely reprogramming support better long-term outcomes. Studies show that addressing minor complications—such as subtle lead migration—can prevent therapy failure (Falowski et al., 2011).
Ultimately, understanding Persistent Spinal Pain can empower patients to advocate for their health and treatment options.
When patient selection, psychology, trial response, and technique are aligned, spinal cord stimulation provides high rates of success for individuals with persistent spinal pain following surgery.
Summary
Persistent Spinal Pain requires a multifaceted approach to achieve optimal management and relief.
Failed Back Surgery Syndrome, now more accurately termed Persistent Spinal Pain Syndrome Type 2 (PSPS-T2), is a complex condition in which chronic back or leg pain continues despite one or more spine surgeries. The underlying mechanisms often involve nerve root irritation, central sensitization, postoperative scarring, or biomechanical changes—problems that medications, injections, and physical therapy frequently cannot resolve long-term. For many patients, Spinal Cord Stimulation (SCS) offers a highly effective, targeted, and reversible treatment option.
SCS works by delivering controlled electrical signals to the spinal cord, modifying abnormal pain transmission before these signals reach the brain. Multiple randomized controlled trials and long-term studies have shown that SCS provides superior relief for neuropathic leg and back pain, improves daily function, reduces medication reliance, and enhances overall quality of life compared with conventional treatments. Modern technologies—including high-frequency and burst stimulation—offer relief without tingling sensations, making therapy more comfortable for a broad range of patients.
For patients with Persistent Spinal Pain, finding the right balance of treatments can be the key to success.
The procedure itself is minimally invasive and performed in two stages: a short trial to confirm benefit, followed by permanent implantation for patients who respond well.
Compared with other treatment options, SCS stands out. Repeated surgeries often provide diminishing benefit, while medications carry risks of dependency and systemic side effects. Epidural injections or minimally invasive procedures may offer short-term relief but rarely address the underlying neuropathic mechanisms driving PSPS-T2. In contrast, SCS directly targets these pathways, providing sustained improvement supported by strong, multi-study evidence. Recent network meta-analysis also identifies neuromodulation as the most effective overall therapy for PSPS-T2.
For many patients, it offers the possibility of returning to normal activities, reducing medication use, and regaining long-term control over chronic spinal pain.
Persistent Spinal Pain management strategies should always be personalized to individual needs.
With a favorable safety profile, reversibility, and robust clinical evidence, SCS represents a modern, science-driven solution for individuals whose pain persists despite surgical and conservative treatments. For many patients, it offers the possibility of returning to normal activities, reducing medication use, and regaining long-term control over chronic spinal pain.
Overall, SCS stands out as the most evidence-supported, durable, and patient-centered option for managing persistent spinal pain after surgery.
References
Those struggling with Persistent Spinal Pain may benefit from support groups and community resources.
De Andrés, J., Van Buyten, J. P., Sokal, P., Huygen, F., & Al-Kaisy, A. (2017). High-density and burst stimulation: New waveforms in spinal cord stimulation. Neuromodulation, 20(6), 533–543.
Falowski, S. M., Celii, A., & Sharan, A. (2011). Spinal cord stimulation: Management of complications and technical failures. Neuromodulation, 14(6), 436–444.
Goudman, L., De Andrés, J., Johnson, S., Al-Kaisy, A., Van Buyten, J. P., Duarte, R. V., … Moens, M. (2025). Comparative effectiveness of treatments for Persistent Spinal Pain Syndrome Type 2: A network meta-analysis. Communications Medicine, 4(1), 1–14.
Grider, J. S., Manchikanti, L., Carayannopoulos, A., Sharma, M. L., Balog, C. C., Harned, M. E., Grami, V., Justiz, R., Nouri, K. H., Hayek, S. M., Vallejo, R., & Christo, P. J. (2016). Effectiveness of spinal cord stimulation in chronic spinal pain: A systematic review. Pain Physician, 19(1), E33–E54.
Kapural, L., Yu, C., Doust, M. W., Gliner, B. E., Vallejo, R., Sitzman, B. T., … Amirdelfan, K. (2015). Novel 10-kHz high-frequency therapy is superior to traditional spinal cord stimulation for the treatment of chronic back and leg pain: The SENZA randomized controlled trial. Anesthesiology, 123(4), 851–860.
Kumar, K., North, R., Taylor, R., Sculpher, M., Van den Abeele, C., Gehring, M., … Buchser, E. (2005). Spinal cord stimulation vs. conventional medical management for failed back surgery syndrome: Study protocol of the PROCESS trial. Neuromodulation, 8(4), 213–218.
Kumar, K., Taylor, R. S., Jacques, L., Eldabe, S., Meglio, M., Molet, J., … North, R. (2007). Spinal cord stimulation versus conventional medical management for neuropathic pain: A multicentre randomized controlled trial in patients with failed back surgery syndrome (PROCESS). Pain, 132(1–2), 179–188.
Manchikanti, L., Grider, J. S., Carayannopoulos, A., Sharma, M. L., Balog, C. C., Harned, M. E., Grami, V., Hayek, S. M., Vallejo, R., & Christo, P. J. (2016). Effectiveness of spinal cord stimulation in chronic spinal pain: A systematic review. Pain Physician, 19(1), E33–E54.
Nissen, M., Ikäheimo, T. M., Huttunen, J., Leinonen, V., & von und zu Fraunberg, M. (2018). Long-term outcome of spinal cord stimulation in failed back surgery syndrome: 20 years of experience in 224 patients. Neurosurgery, 84(6), 1230–1238.
North, R. B., Kidd, D. H., Farrohki, F., & Piantadosi, S. (2005). Spinal cord stimulation versus repeated lumbosacral spine surgery for chronic pain: A randomized, controlled trial. Neurosurgery, 56(1), 98–107.
North, R. B., Kumar, K., Wallace, M., Henderson, J. M., Shipley, J., Hernandez, J., … Jaax, K. N. (2011). Spinal cord stimulation versus re-operation in patients with failed back surgery syndrome: An international multicenter randomized controlled trial (EVIDENCE). Neuromodulation, 14(4), 330–335.
Palmer, N., Guan, Z., & Chai, N. C. (2019). Spinal cord stimulation for failed back surgery syndrome: Patient selection considerations. Translational Perioperative Pain Medicine, 6(3), 81–90.
Sweet, J., Mitchell, L. S., Narouze, S., Sharan, A., & Falowski, S. (2016). Spinal cord stimulation for chronic pain: Mechanism of action, indications, and outcomes. The Clinical Journal of Pain, 32(9), 830–838.